louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02841982: Quadratus Lumborum Block : Effect on Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Laparoscopic Renal Surgery
Pain Management
Nerve Block
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2016-07-22
Enrollment: 30
Sex: ALL
Minimum age (years): 17
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This prospective, randomized study,control study aims to compare the analgesic effect,opioids consumption,quality of recovery,length of hospital stay and incidence of chronic pain,et al. between single-injection QLB(quadratus lumborum block)+ intravenous patient-controlled analgesia (IPCA) and intravenous patient-controlled analgesia (IPCA) alone in patients undergoing laparoscopic renal surgeries.


Eligibility criteria: Inclusion Criteria:

* Age 18-70 yrs
* American Society of Anesthesiologists physical statusⅠ-Ⅲ
* Undergo laparoscopic nephrectomy
* Informed consent

Exclusion Criteria:

* A known allergy to the drugs being used
* Coagulopathy, on anticoagulants
* Analgesics intake, history of substance abuse
* Participating in the investigation of another experimental agent
* Inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)

Primary outcomes:
measure: cumulative morphine consumption
timeFrame: within 48 postoperative hours
Secondary outcomes:
measure: The pain scores determined by the numeric rating scale (NRS, 0-10)
timeFrame: At 0, 2,4, 8, 12, 24 ,48,72hours after the surgery
measure: nausea and vomiting score
timeFrame: within 24 hours after the surgery
measure: pruritus score
timeFrame: within 24hour after the surgery
measure: ambulation time
timeFrame: within the 7 days after surgery
measure: time of recovery of bowl movement
timeFrame: within the 5 days after surgery
measure: quality of recovery
timeFrame: 3days and 5days after surgery
measure: Postoperative hospital length of stay
timeFrame: Up to 6 weeks
measure: patient satisfaction with anesthesia
timeFrame: 48 hours after surgery
Other outcomes:
Locations:
city: Beijing
country: China
facility: Xulei CUI
state: Beijing
Study officials:
affiliation: Peking Union Medical College Hospital
name: Yuguang Huang, MD.
role: STUDY_CHAIR
References:
Clinical trial NCT04286282: Neuroinflammation and Modulating Factors in Depression and HIV
Official title: Neuroinflammation and Modulating Factors in Depression and HIV: The Growth Study-Group Therapy in HIV for Depression IN Uganda
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Depression
HIV
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2020-02-26
Enrollment: 109
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Determine if depression, which persists after depression treatment at 26 weeks, is associated with increased innate inflammation in a prospective cohort of HIV-infected Ugandans receiving SSRIs in which group psychotherapy is initiated.

Detailed description: Depression in HIV is a complex co-morbidity with both social factors such as stigma as well as biologic components. Disruptions in neurotransmitters such as serotonin and catecholamines are known to cause depression. Inflammation caused by diseases such as stroke, diabetes, and HIV is associated with higher rates of depression. HIV causes inflammation throughout the body, but since the virus can cross the blood-brain-barrier, HIV can replicate in and target the brain causing neuroinflammation which predisposes depression. However the pathophysiology of the role of inflammation in comorbid depression and HIV is poorly understood.

1. Among depressed HIV-infected Ugandans, determine if the resolution of depression at 26 weeks of HIV therapy is improved with group psychotherapy.
2. In the same population determine if persistent depression is associated with higher levels of innate inflammation. Also, compare baseline and follow up inflammation among depressed compared to non-depressed control group.
3. Evaluate if viral suppression levels at 26 weeks are improved by group psychotherapy.

Eligibility criteria: Inclusion Criteria:

For the depressed patient arm,

* Newly-presenting clinic patients (\<3 months)
* Mild to Moderately-Severe Depressive Symptoms with PHQ-9 score \>5 but \<20
* Not suicidal (PHQ-9 question 9 score \>2)
* Not receiving antiretroviral therapy (ART) at screening
* Outpatient, not requiring hospitalization

For the non-depressed patient arm,

* Newly-presenting clinic patients (\<3 months)
* Not suicidal (PHQ-9 question 9 score \>2)
* Not receiving antiretroviral therapy (ART) at screening
* Outpatient, not requiring hospitalization

Exclusion Criteria:

- No additional exclusion criteria

Primary outcomes:
measure: Change in Patient Health Questionnaire (PHQ)-9
timeFrame: 3 months
measure: Change in Patient Health Questionnaire (PHQ)-9
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Kampala
country: Uganda
facility: Infectious Diseases Institute
Study officials:
affiliation: University of Minnesota
name: Sarah Lofgren, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00196482: Human Milk Fortifiers and Acid-Base Status
Official title: Impact of Human Milk Fortifiers on Acid-Base Status in Preterm Infants
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Premature Birth
Keywords: growth
oral feeding
nutrition
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
Collaborators: name: NUMICO,Dr. Heike Mueller, Friedrichsdorf, Germany
First posted: 2005-09-20
Enrollment: 30
Sex: ALL
Minimum age (years): 10
Maximum age (years): 3
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Double-blind randomized controlled trial to investigate the impact of two human milk fortifiers on acid-base status and longitudinal growth and weight gain in preterm infants.

Two different compositions are tested, main difference is in electrolyte composiiton.

Detailed description: Two groups each consisting of 15 infants with a birth weight below 2000g are studied.randomization is startified by three birth weigth classes (\<1000g, 1000-1500g,1500 - 2000g) human milk fortifier is introduced in two steps after oral feeding is achieved. two acid-base status and electrolyte concentrations are measured. when metabolic acidosis, defined as BE \< -6 mmol/l, occurs fortifier feeding is stopped, and after a wash-out period of three days the alternative product is used.again, occurence of metabolic acidosis, need for oral bicarbonate and effect on longitudinal growth an weight gain are registered.

Eligibility criteria: Inclusion Criteria:

growing premature infants with a birth weight \< 2000g

Exclusion Criteria:

congenital malformation chromosomal disorders sepsis metabolic disorders need for mechanical ventilation

Primary outcomes:
measure: frequency of metabolic acidosis
Secondary outcomes:
measure: need for oral bicarbonate administartion
measure: longitudinal growth
measure: weight gain
measure: amino acid levels in plasma an urine
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: University Hospital
state: M-V
Study officials:
affiliation: Department of Neonatology, University Hospital Greifswald
name: Christoph Fusch
role: STUDY_CHAIR
References:
citation: Amari S, Shahrook S, Namba F, Ota E, Mori R. Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.
Clinical trial NCT05332782: Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry
Official title: Outcomes of Patients tReated wIth Mitral Transcatheter Edge-to-edge Repair for Primary Mitral Regurgitation Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Mitral Regurgitation
Lead sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2022-04-18
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients undergoing transcatheter edge-to-edge repair for primary mitral regurgitation

Brief summary: This multinational, non-interventional, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent mitral valve transcatheter edge-to-edge repair (M-TEER) for primary mitral regurgitation (PMR).


Eligibility criteria: Inclusion Criteria:

* clinically significant primary mitral regurgitation
* patient underwent M-TEER
* echocardiography data at baseline, procedure and follow-up
* follow-up of at least 12 months

Exclusion Criteria

* age under 18 years

Primary outcomes:
measure: All-cause mortality
timeFrame: 12 months
measure: Cardiovascular mortality
timeFrame: 12 months
measure: Rehospitalization for congestive heart failure
timeFrame: 12 months
measure: Re-do mitral valve procedure
timeFrame: 12 months
Secondary outcomes:
measure: Residual mitral regurgitation
timeFrame: up to 30 days
measure: Residual mitral regurgitation
timeFrame: 12 months
measure: MVARC (Mitral Valve Academic Research Consortium) Technical success
timeFrame: 1 day (at exit from the catheterization laboratory)
measure: Functional success
timeFrame: 1 day (at exit from the catheterization laboratory)
Other outcomes:
Locations:
city: New York
country: United States
facility: Montefiore Medical Center
state: New York
city: Bordeaux
country: France
facility: Centre Hospitalier de Bordeaux
city: Lille
country: France
facility: Université Lille, Inserm, Centre Hospitalier Universitaire de Lille
city: Rennes
country: France
facility: University Hospital of Rennes, Centre Hospitalier de Rennes
city: Hamburg
country: Germany
facility: University Heart & Vascular Center Hamburg
city: Munich
country: Germany
facility: Klinikum der Universität München
Study officials:
affiliation: University Heart & Vascular Center Hamburg
name: Daniel Kalbacher, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01127282: The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A
Official title: The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A: a Randomized-controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: H1N1 Influenza
Keywords: influenza
vitamin
improvement of symptom
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2010-05-20
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Influenza continues to inflict an important burden on health-care systems. The 2009 H1N1 influenza virus first appeared in Mexico and the United States in March and April 2009 and has swept the globe with unprecedented speed.

The aim of this study is to evaluate effect of supplement vitamin on the clinical course of patients with acute respiratory illness suspected novel H1N1 infection.

Detailed description: Patients with acute respiratory illness randomized to control or vitamin groups. The patients completed questionnaire about their initial symptom scores. After 5 days of vitamin trial, patients were asked about their symptom by telephone survey.

Eligibility criteria: Inclusion Criteria:

* Age \> 20 years
* Acute respiratory illness suspected H1N1 infection
* Acute febrile respiratory illness(BT \> 37.8) and throat pain or cough or nasal congestion

Exclusion Criteria:

* Pregnancy
* Hypersensitivity to vitamin A
* History of liver disease or renal disease
* Urinary stone disease

Primary outcomes:
measure: change of symptom score
timeFrame: 1 week after initial visit
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center
Study officials:
affiliation: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul Metropolitan Government, Seoul National University Boramae Medical Center
name: Chang-Hoon Lee, MD
role: STUDY_CHAIR
References:
Clinical trial NCT00396682: Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma
Official title: Elimination of CD4+CD25+ Regulatory T Cells in Patients With Advanced HCC After Treatment With Cyclophosphamide
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Advanced HCC
Keywords: HCC
T cell
Lead sponsor: Hannover Medical School
Sponsor class: OTHER
First posted: 2006-11-07
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses in patients with advanced HCC.


Eligibility criteria: Inclusion Criteria:

* adequate WBC
* adequate liver and kidney function
* no immunodeficiency
* ECOG \< 2

Exclusion Criteria:

* advanced liver cirrhosis
* severe cardiopulmonary diseases

Primary outcomes:
measure: Frequency of CD4+CD25+regulatory T cells
timeFrame: within 8 weeks
measure: Tumor specific immune responses
timeFrame: within 12 weeks
Secondary outcomes:
measure: Toxicity
timeFrame: within 8 weeks
measure: Function and Phenotype of CD4+CD25+ regulatory T cells
timeFrame: within 12 weeks
measure: Tumor response
timeFrame: within 12 weeks
measure: Survival
timeFrame: 6 months
Other outcomes:
Locations:
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
Study officials:
affiliation: Department of Gastroenterology, Medizinische Hochschule Hannover
name: Tim F Greten, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hannover Medical School
name: Tim F Greten, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Greten TF, Ormandy LA, Fikuart A, Hochst B, Henschen S, Horning M, Manns MP, Korangy F. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother. 2010 Feb-Mar;33(2):211-8. doi: 10.1097/CJI.0b013e3181bb499f.
Clinical trial NCT02293382: A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Official title: A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: MPS IIIB (Sanfilippo Syndrome)
Keywords: MPS IIIB
Mucopolysaccharodosis III
Mucopolysaccharidosis type IIIB
Sanfilippo Syndrome
Lead sponsor: Alexion Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2014-11-18
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 deceased patients with MPS IIIB

Brief summary: The objective is to perform a retrospective chart review to generate data to evaluate the clinical characteristics and course of disease progression of MPS IIIB.


Eligibility criteria: Inclusion Criteria:

1. The deceased patient was diagnosed with MPS IIIB as determined by either of the following:

   1. Documented deficiency of NAGLU enzyme activity.
   2. Documented functionally-relevant mutations in both alleles of the NAGLU gene.
2. Patient's parent or legal guardian provides informed consent (unless the requirement for informed consent is waived by local regulations).
3. The availability of pre-defined information in the patient's clinical chart:

Exclusion Criteria:

There are no exclusion criteria for this study.

Primary outcomes:
measure: Evaluation of disease presentation and the course of disease progression including the end stage of the disease in patients with MPS IIIB, assessed from medical history data obtained by retrospective chart review of deceased patients.
timeFrame: N/A as this is a retrospective chart review of deceased patients
Secondary outcomes:
Other outcomes:
Locations:
city: Pittsburg
country: United States
state: Pennsylvania
city: Porte Alegre
country: Brazil
city: Amsterdam
country: Netherlands
city: Barcelona
country: Spain
city: Birmingham
country: United Kingdom
Study officials:
References:
Clinical trial NCT03772782: Relationship of SmartPhone Use Addiction With Musculoskeletal System and Cognitive Flexibility
Official title: Investigation of the Relationship of Smart Phone Use Addiction With Musculoskeletal System Problems and Cognitive Flexibility
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Smartphone
Musculoskeletal
Cognitive Flexiblity
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2018-12-11
Enrollment: 325
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: university students between the ages of 18-25

Brief summary: Smartphones have become a part of everyday life, but with some problems. Researches have pointed out that smartphone addiction can cause both physical and mental problems.

Detailed description: Smartphones have become a part of everyday life, but with some problems. Developments in communication technologies have also improved the capacities and limits of smartphones. This has led to the increased availability of smartphones in daily life. Smartphones have become a part of everyday life, but with some problems. Smartphone addiction has been an important topic of research and discussion as a type of addiction that develops depending on the frequency of smartphone use. Researches have pointed out that smartphone addiction can cause both physical and mental problems. As a result of a study conducted in the literature, continuous use of smartphones has been found to cause sleep disturbances, stress, anxiety, decrease in physical activities and many diseases. In this study, the relationship between the concept of smartphone addiction and musculoskeletal problems and cognitive flexibility in young people will be investigated.

Eligibility criteria: Inclusion Criteria:

* University students
* Without any known physical and/or psychological disorders
* Using a smartphone
* Volunteer

Exclusion Criteria:

Have any physical and/or psychological disorders

Primary outcomes:
measure: Smartphone addiction scale score
timeFrame: at the end of the third month
Secondary outcomes:
Other outcomes:
Locations:
city: Edirne
country: Turkey
facility: Özgü İnal
Study officials:
affiliation: Trakya University
name: ÖZGÜ İNAL
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04377282: The Effect of Buckwheat and Couscous on Satiety and Food Intake in Young Adults
Official title: The Effect of Buckwheat on Blood Glucose, Satiety and Food Intake
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food
Eating
Appetite
Lead sponsor: Mount Saint Vincent University
Sponsor class: OTHER
First posted: 2020-05-06
Enrollment: 22
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Randomized crossover
Primary purpose: BASIC_SCIENCE

Brief summary: A diet rich in whole grains has been linked to multiple beneficial health outcomes, including cardiovascular health, weight loss and a decreased risk of acquiring type 2 diabetes. However, grain products vary due to their botanical origin, composition, and post-harvest processing. While wheat is considered a dominant grain crop in Canada, the minor crops, including gluten-free buckwheat, become popular alternatives to wheat products such as couscous. Both buckwheat groats and couscous are traditionally consumed in the form of the porridge or side dish, however, their acute effects on satiety and food intake remain unknown. The objective of this study is to investigate the short-term effects of couscous and buckwheat on satiety and short-term food intake in young adult males.


Eligibility criteria: Inclusion Criteria:

* Healthy
* 18-30 years

Exclusion Criteria:

* Smokers
* Taking medication
* Breakfast skippers

Primary outcomes:
measure: Food intake
timeFrame: 120 minutes
measure: Subjective appetite
timeFrame: 0-120 minutes
Secondary outcomes:
measure: Subjective feeling of physical comfort
timeFrame: 0-120 minutes
measure: Subjective perception of food palatability (pleasantness)
timeFrame: 0, 120 minutes
Other outcomes:
Locations:
city: Halifax
country: Canada
facility: Mount Saint Vincent University
state: Nova Scotia
Study officials:
affiliation: Mount Saint Vincent University
name: Bohdan L. L Luhovyy, PhD
role: PRINCIPAL_INVESTIGATOR
References: